This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Leah J. Witt, MD: ...

Symptoms of dyspnea in a patient with chronic obstructive pulmonary disease (COPD), which were caused by pulmonary hyperinflation, were improved by endobronchial valve treatment. Endobronchial valve ...

Researchers from Humana Healthcare Research and University of Chicago Medicine found that Medicare Advantage members with COPD and low medication adherence significantly improved their ...

Positive data from the MIRANDA trial follows the OBERON and TITANIA studies of tozorakimab in COPD.

Considering a risk score generated from multiple genetic variants linked to chronic obstructive pulmonary disease (COPD) caught undiagnosed cases of the disease better than conventional risk factors ...

A study analyzed the personal and family history of patients who developed chronic obstructive pulmonary disease (COPD) before age 50. Although the development of chronic obstructive pulmonary disease ...

Tozorakimab is an investigational monoclonal antibody designed to bind and inhibit interleukin-33 (IL-33), an alarmin cytokine. This targeted approach is expected to reduce airway inflammation and ...

“It is likely that the poor socioeconomic and medical outcomes in patients with mild COPD are caused both by mild COPD and comorbidities…The findings clearly show that COPD constitutes a condition ...

The decrease in global cancer mortality. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract does not include a full text component.